James Noble

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Abingdon, Oxfordshire
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Amy Garabedian, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for James Noble

Form 4 holding Director

Adaptimmune Therapeutics PLC

Security class
Option to purchase Ordinary Shares
Shares / value
710,711
Estimated value
Report date
01 Jul 2022
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

LAVA Therapeutics NV

Security class
Common Shares (Right to Buy)
Shares / value
33,390
Estimated value
Report date
13 Feb 2025
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Director

GW PHARMACEUTICALS PLC

Security class
Share Options
Shares / value
0
Estimated value
Report date
05 May 2021
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount

Insider Reports Filed by James Noble

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .